Injection Therapy for Peyronie’s Disease

Abstract

Peyronie’s disease (PD) is an underdiagnosed condition that affects up to 9 % of the male population. Intralesional injection therapy (ILI) is one of many modalities in the treatment of PD. Corticosteroids were the first known employed ILI agent but is presently not recommended due to its unproven efficacy. ILI of verapamil, a calcium channel blocker, and interferon have displayed some promising results with regard to improvements in plaque size, penile curvature and erectile function. Their use for the treatment of PD, however, remains off-label. Based on the positive results of the IMPRESS 1 and 2 trials, ILI of collagenase clostridium histolyticum became the first FDA-approved drug for the treatment of PD in 2013. When combined with ILI, penile traction therapy may prevent PD-related loss of penile length, if used diligently. Finally, ILI of stem cells, while still in its infancy, offers hope for a more targeted treatment of the disease in the future.